Christopher L. Reading
Technik-/Wissenschafts-/F&E-Leiter bei Harbor Therapeutics, Inc.
Vermögen: 18 165 $ am 30.04.2024
Profil
Christopher L.
Reading is currently the Chief Scientific Officer at Harbor Therapeutics, Inc. He previously held positions as Vice President-Product & Process Development at Systemix, Inc. and Novartis, Inc. He also served as Chief Scientific Officer at Harbor Diversified, Inc. and was an Associate & Assistant Professor at The University of Texas M.D.
Anderson Cancer Center.
Reading holds a doctorate from the University of California, Berkeley and an undergraduate degree from the University of California San Diego.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BIOVIE INC. CLASS A
0,07% | 16.02.2023 | 37 148 ( 0,07% ) | 18 165 $ | 30.04.2024 |
Aktive Positionen von Christopher L. Reading
| Unternehmen | Position | Beginn |
|---|---|---|
Harbor Therapeutics, Inc.
 Harbor Therapeutics, Inc. BiotechnologyHealth Technology Harbor Therapeutics, Inc. develops a proprietary class of adrenal steroid hormones as novel pharmaceuticals and nutraceuticals for human health. The company is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1999 |
Ehemalige bekannte Positionen von Christopher L. Reading
| Unternehmen | Position | Ende |
|---|---|---|
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Corporate Officer/Principal | - |
Novartis, Inc.
 Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco. | Corporate Officer/Principal | - |
Systemix, Inc.
 Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Corporate Officer/Principal | - |
| HARBOR DIVERSIFIED, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Christopher L. Reading
| University of California, Berkeley | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| HARBOR DIVERSIFIED, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Novartis, Inc.
Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco. | Health Technology |
Systemix, Inc.
Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Health Services |
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Consumer Services |
Harbor Therapeutics, Inc.
Harbor Therapeutics, Inc. BiotechnologyHealth Technology Harbor Therapeutics, Inc. develops a proprietary class of adrenal steroid hormones as novel pharmaceuticals and nutraceuticals for human health. The company is headquartered in San Diego, CA. | Health Technology |
